Predict your next investment

Academic/University
gladstone.org

See what CB Insights has to offer

Portfolio Exits

1

Partners & Customers

8

About Gladstone Institutes

Gladstone Institutes aims to unravel the basics of biology in order to better understand, prevent, treat, and cure cardiovascular, viral, and neurological conditions such as heart failure, HIV/AIDS and Alzheimer's disease. Through an affiliation agreement with the University of California, San Francisco (UCSF), the Gladstone Institutes was founded as a research and training facility.

Gladstone Institutes Headquarter Location

1650 Owens Street

San Francisco, California, 94158,

United States

415-734-2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Gladstone Institutes News

It Takes Guts to Make a Heart

Dec 3, 2021

12/02/2021 | 05:52pm EST Message : *Required fields SAN FRANCISCO, Dec. 2, 2021 /PRNewswire/ -- At the earliest stages of a new human life, cells that seem identical begin to divide into distinct types that eventually grow into a diverse array of tissues and organs. During this process, neighboring tissues exchange chemical signals that prompt different steps of each other's development. But this crosstalk is complex and dynamic, and therefore difficult to study. Now, scientists at Gladstone Institutes have discovered how to grow a new kind of organoid—a three-dimensional, organ-like cluster of cells—that mimics how gut and heart tissues arise cooperatively from stem cells. This first-of-its-kind organoid could serve as a new tool for laboratory research into signaling between tissues that is essential for healthy human development. "Our research highlights promising new dimensions for organoid technologies that could improve our understanding of how developing organs and tissues cooperate and instruct each other," says Gladstone Senior Investigator Todd McDevitt, PhD, the senior author of a new study published in the journal Cell Stem Cell. A Serendipitous New Organoid McDevitt's lab has been leading efforts in engineering new ways to grow organoids, which are miniature multi-cell structures that reproduce, in the dish, the features and functions of the heart, brain, lungs, and other organs. His team creates heart organoids from human induced pluripotent stem cells. They coax these cells into becoming heart cells by growing them in various cocktails of nutrients and other naturally occurring substances. While a conventional cocktail yields mostly heart muscle cells, the scientists tried a different cocktail that might allow a greater variety of heart cells to form. They did not originally set out to create a new kind of organoid. Yet to their surprise, they found that in a number of cases, the new cocktail led to organoids that contained not only heart, but also gut cells. "We were intrigued because organoids normally develop into a single type of tissue—for example, heart tissue only," says Ana Silva, PhD, a postdoctoral scholar in the McDevitt Lab and first author of the new study. "Here, we had both heart and gut tissues growing together in a controlled manner, much as they would in a normal embryo." These organoids offer a promising new way to examine the crosstalk between developing tissues, which has so far relied on growing single-tissue organoids separately and then attempting to combine them. Painting a Full Picture of the New Organoid The researchers found that compared to conventional heart organoids, the new organoids resulted in much more complex and mature heart structures—including some resembling more mature-like blood vessels. The types and proportions of heart cells in the new organoids, and their electrical properties, were highly similar to those of real fetal hearts. By contrast, cells in conventional organoids, which do not contain gut tissue, remain stuck at a much earlier stage of their transformation into heart cells. "Once it became clear that the presence of the gut tissue contributed to the maturity of the heart tissue, we realized we had arrived at something new and special," says McDevitt, who is also a professor of bioengineering and therapeutic sciences at UC San Francisco. The scientists also showed that gut tissue in the new organoids matured into a variety of recognizable structures and cell types, particularly of the small intestine. Moreover, the gut and heart cells in the new organoids released chemicals known to be involved in signaling between the two tissues during heart development. "It is a beautiful, dynamic model of heart development," says Silva. "Our findings suggest a way to conduct this research in a more realistic context, where both gut and heart tissues develop together from the same starting materials." A Robust System for Research The researchers have been able to keep the new organoids alive in a dish for more than 1 year, which is a very long time for anything grown in the lab, especially a large 3D aggregate of cells. This durability suggests that similar organoids could be grown to serve as robust systems for prolonged laboratory research. And while the organoids likely cannot perfectly capture every part of real heart and gut development, they could help deepen the understanding of this cooperative process. In addition to shedding new light on healthy human development, the organoids could help clarify how that process can go wrong. For instance, they could prove valuable for research into congenital disorders that are known to affect both heart and gut development, such as chronic atrial and intestinal dysrhythmias. Further research will be needed to refine methods for growing these organoids reliably, so they can be used to their full potential. And in the future, researchers could theoretically develop other, similar organoids involving different pairs of tissues, such as heart and lung, or lung and kidney. "Communication between developing tissues is perhaps not yet as widely appreciated as it should be," McDevitt says. "We can now potentially explore this fundamental process in a way we never conceived of before." About the Study Other authors are Oriane Matthys, David Joy, Mara A. Kauss, Vaishaali Natarajan, Michael Lai, Diwaker Turaga, Andrew Blair, Michael Alexanian, and Benoit Bruneau of Gladstone. This work was supported by a California Institute of Regenerative Medicine grant (LA1_C14-08015) and the Gladstone BioFulcrum Heart Failure Research Program. About Gladstone Institutes To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impact—unsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with the University of California, San Francisco. Media Contact:

Gladstone Institutes Portfolio Exits

1 Portfolio Exit

Gladstone Institutes has 1 portfolio exit. Their latest portfolio exit was Tenaya Therapeutics on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$991

3

Date

7/30/2021

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

3

Gladstone Institutes Acquisitions

2 Acquisitions

Gladstone Institutes acquired 2 companies. Their latest acquisition was Tenaya Therapeutics on December 07, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/7/2016

Series C

$248M

Spinoff / Spinout

2

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/7/2016

Investment Stage

Series C

Seed VC - II

Companies

Subscribe to see more

Valuation

Total Funding

$248M

$99M

Note

Spinoff / Spinout

Subscribe to see more

Sources

2

10

Gladstone Institutes Partners & Customers

8 Partners and customers

Gladstone Institutes has 8 strategic partners and customers. Gladstone Institutes recently partnered with ChemPartner on April 4, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

4/15/2020

Partner

ChemPartner

China

Article | By Sarah Lively | April 15, 2020. ChemPartner and Gladstone Institutes Announce COVID-19 Research Collaboration

In a new collaboration , Chempartner Corporation , the US arm of a leading pre-clinical contract research and development organization , is partnering with scientists at Gladstone Institutes , an independent biomedical research organization , to accelerate the discovery of novel therapeutics and diagnostics for the novel coronavirus , SARS-CoV-2 .

1

1/14/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/5/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/3/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

10/24/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

4/15/2020

1/14/2020

12/5/2019

12/3/2019

10/24/2019

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

ChemPartner

Country

China

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Article | By Sarah Lively | April 15, 2020. ChemPartner and Gladstone Institutes Announce COVID-19 Research Collaboration

In a new collaboration , Chempartner Corporation , the US arm of a leading pre-clinical contract research and development organization , is partnering with scientists at Gladstone Institutes , an independent biomedical research organization , to accelerate the discovery of novel therapeutics and diagnostics for the novel coronavirus , SARS-CoV-2 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Gladstone Institutes Team

2 Team Members

Gladstone Institutes has 2 team members, including current President, Deepak Srivastava.

Name

Work History

Title

Status

Deepak Srivastava

President

Current

R. Sanders Williams

President

Current

Name

Deepak Srivastava

R. Sanders Williams

Work History

Title

President

President

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.